Neumora Therapeutics, Inc. (NMRA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2026. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for brain and centrally mediated diseases using a precision neuroscience approach. The company has no approved products and has not generated any revenue from product sales. Key pipeline assets include navacaprant (Phase 3 for Major Depressive Disorder), NMRA-511 (Phase 1b/2 for agitation in Alzheimer's disease), NMRA-898 (Phase 1 for schizophrenia), and NMRA-215 (preclinical for obesity).
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(53,458) | $(67,992) |
| Net Loss Per Share (Basic & Diluted) | $(0.30) | $(0.42) |
| Operating Expenses | $52,864 | $70,936 |
| Cash and Cash Equivalents (End of Period) | $147,072 | $128,073 |
| Long-Term Debt (Net) | $52,963 | $54,532 |
| Accumulated Deficit | $(1,237,607) | $(1,015,213) |
| Net Cash Used in Operating Activities | $(46,404) | $(59,448) |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $14.5 million (21%) compared to Q1 2025, driven primarily by lower operating expenses.
- Operating Expense Reduction: Total operating expenses declined by $18.1 million (25%).
- Research & Development (R&D): Decreased by $13.6 million (26%) to $38.6 million. This was due to reduced manufacturing costs for navacaprant, lower clinical trial costs for NMRA-511 following the completion of its Phase 1b study, and the cessation of costs related to the Amgen collaboration which terminated in September 2024.
- General & Administrative (G&A): Decreased by $4.5 million (24%) to $14.3 million, attributed to reduced headcount and lower stock-based compensation.
- Interest Expense: Interest expense of $1.9 million was recorded in Q1 2026 related to the K2 HealthVentures term loan, compared to zero in Q1 2025.
- Debt Conversion: In February 2026, $2.05 million of term loan principal was converted into common stock.
- Equity Financing: The company raised approximately $10.9 million in net proceeds through at-the-market (ATM) equity offerings during the quarter.
Guidance, Outlook, and Risks
- Liquidity: As of March 31, 2026, the company held $147.1 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months. However, the company expects to incur additional losses and will require further capital to complete development and commercialization.
- Clinical Outlook: The company expects to report Phase 3 KOASTAL-2 and -3 topline data for navacaprant in the second quarter of 2026. Data for NMRA-511 and NMRA-898 are expected in the second half of 2026.
- Debt Obligations: The company has a $125 million term loan facility with $60 million drawn as of March 31, 2026. The loan bears a variable interest rate (minimum 10.45%) and matures in May 2029. A minimum liquidity covenant becomes effective July 1, 2026.
- Legal Proceedings: A putative securities class action lawsuit regarding the 2023 IPO is ongoing. The defendants filed a motion to dismiss the second amended complaint, with a hearing date not yet scheduled.
- Risk Factors: Significant risks include the failure of clinical trials (noting the KOASTAL-1 study did not meet its primary endpoint in January 2025), the need for additional financing, potential dilution from debt conversion or equity offerings, and contingent milestone payments from asset acquisitions (BlackThorn, Vanderbilt, Amgen) totaling hundreds of millions of dollars.
Investor Verification Checklist
- Verify the specific timeline and data readout dates for the Phase 3 navacaprant trials (KOASTAL-2 and -3) in Q2 2026.
- Confirm the terms of the K2 HealthVentures loan, specifically the liquidity covenant thresholds effective July 1, 2026, and the conversion rights held by the lender.
- Review the status of the securities class action litigation regarding the 2023 IPO and any potential financial impact.
- Assess the burn rate relative to the $147.1 million cash balance to validate the 12-month liquidity runway.
- Monitor the status of contingent milestone payments owed to BlackThorn, Vanderbilt, and Amgen, which could require significant cash or equity settlements upon future regulatory or commercial achievements.